Coloplast advances its long-term strategy despite challenges on many fronts

The pandemic in China, inflation, bottlenecking, and more: Coloplast’s problems are many, but work to meet goals set in Strive25, the medtech firm’s long-term plan, is still ongoing.

Photo: Coloplast / PR

Coloplast is still engaged with its long-term strategy entitled Strive25, and notes progress in 2021/2022. However, challenges such as lockdowns in China due to Covid-19, inflation, bottlenecking, and a searing hot labor market are looming on the horizon.

CEO Kristian Villumsen updated the media on Coloplast’s progress during the Danish medtech company’s ”Meet the Management” day, which took place on Wednesday.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs